Optic neuropathy linked to ACAD9 pathogenic variants: A potentially riboflavin-responsive disorder?

Mitochondrion. 2021 Jul:59:169-174. doi: 10.1016/j.mito.2021.05.002. Epub 2021 May 20.

Abstract

Mitochondrial complex I (CI) deficiencies (OMIM 252010) are the commonest inherited mitochondrial disorders in children. Acyl-CoA dehydrogenase 9 (ACAD9) is a flavoenzyme involved chiefly in CI assembly and possibly in fatty acid oxidation. Biallelic pathogenic variants result in CI dysfunction, with a phenotype ranging from early onset and sometimes fatal mitochondrial encephalopathy with lactic acidosis to late-onset exercise intolerance. Cardiomyopathy is often associated. We report a patient with childhood-onset optic and peripheral neuropathy without cardiac involvement, related to CI deficiency. Genetic analysis revealed compound heterozygous pathogenic variants in ACAD9, expanding the clinical spectrum associated to ACAD9 mutations. Importantly, riboflavin treatment (15 mg/kg/day) improved long-distance visual acuity and demonstrated significant rescue of CI activity in vitro.

Keywords: ACAD9; Complex I; Optic neuropathy; Riboflavin.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acyl-CoA Dehydrogenases / genetics*
  • Age of Onset
  • Child
  • Frameshift Mutation*
  • Heterozygote
  • Humans
  • Male
  • Optic Nerve Diseases / drug therapy*
  • Optic Nerve Diseases / genetics
  • Riboflavin / administration & dosage*
  • Riboflavin / therapeutic use
  • Treatment Outcome

Substances

  • Acyl-CoA Dehydrogenases
  • ACAD9 protein, human
  • Riboflavin